CalciMedica shares are trading lower. The stock initially gained after the company announced topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis but has reversed.
Portfolio Pulse from Benzinga Newsdesk
CalciMedica shares are trading lower after initially gaining on the announcement of topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis.
June 27, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CalciMedica shares are experiencing a decline after an initial rise following the announcement of topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis.
The initial positive reaction to the Phase 2b trial data was not sustained, leading to a reversal in the stock price. This suggests that investors may have had higher expectations or found the data less promising upon closer inspection.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100